SEARCH

SEARCH BY CITATION

References

  • 1
    Perry RD, Fetherston JD. Yersinia pestis – etiologic agent of plague. Clin Microbiol Rev 1997; 10:3566.
  • 2
    World Health Organization (WHO). Plague. Democratic Republic of the Congo. Wkly Epidemiol Rec 2005; 2005:138140.
  • 3
    Russell P, Eley SM, Hibbs S et al. A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 1995; 13:15511556.
  • 4
    Williamson ED, Eley SM, Griffin KF et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 1995; 12:223230.
  • 5
    Heath DG, Anderson GW, Mauro JM et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998; 16:11311137.
  • 6
    Demeurre CE. Live vaccines against plague and pseudotuberculosis. In: Carniel E , Hinnebusch BJ , eds. Yersinia systems biology and control. Norfolk, UK: Caister Academic Press, 2012:143168.
  • 7
    Hawgood BJ. Alexandre Yersin (1863–1943): discoverer of the plague bacillus, explorer and agronomist. J Med Biogr 2008; 16:167172.
  • 8
    Achtman M, Zurth K, Morelli G et al. Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis. Proc Natl Acad Sci USA 1999; 96:1404314048.
  • 9
    Hinnebusch BJ, Perry RD, Schwan TG. Role of the Yersinia pestis hemin storage (hms) locus in the transmission of plague by fleas. Science 1996 273:367370.
  • 10
    Zhou D, Yang R. Molecular Darwinian evolution of virulence in Yersinia pestis. Infect Immun 2009; 77:22422250.
  • 11
    Eisen RJ, Bearden SW, Wilder AP et al. Early-phase transmission of Yersinia pestis by unblocked fleas as a mechanism explaining rapidly spreading plague epizootics. Proc Natl Acad Sci USA 2006; 103:1538015385.
  • 12
    Hinnebusch BJ, Sebbane F, Vadyvaloo V. Transcriptional profiling of the Yersinia pestis lifecycle. In: Carniel E , Hinnebusch BJ , eds. Yersinia systems biology and control. Norfolk, UK: Caister Academic Press, 2012:118.
  • 13
    Hu P, Elliott J, McCready P et al. Structural organization of virulence-associated plasmids of Yersinia pestis. J Bacteriol 1998; 180:51925202.
  • 14
    LindlerLE,Plano GV, Burland V et al. Complete DNA sequence and detailed analysis of the Yersinia pestis KIM5 plasmid encoding murine toxin and capsular antigen. Infect Immun 1998; 66:57315742.
  • 15
    Perry RD, Straley SC, Fetherston JD et al. DNA sequencing and analysis of the low-Ca2+-response plasmid pCD1 of Yersinia pestis KIM5. Infect Immun 1998; 66:46114623.
  • 16
    Protsenko OA, Anisimov PI, Mozharov OT et al. Detection and characterization of Yersinia pestis plasmids determine pesticin I, fraction I antigen and ‘mouse’ toxin synthesis. Genetika 1983; 19:10811090.
  • 17
    Cherepanov P, Mikhailova TG, Farimova GA et al. Cloning and detailed mapping of the Fra-Ymt region of the Yersinia pestis plasmid pFra. Mol Gen Microbiol Virol 1991; 12:1926.
  • 18
    Hinnebusch BJ, Fischer ER, Schwan TG. Evaluation of the role of the Yersinia pestis plasminogen activator and other plasmid-encoded factors in temperature-dependent blockage of the flea. J Infect Dis 1998; 178:14061415.
  • 19
    Vadyvaloo V, Jarrett C, Sturdevant DE et al. Transit through the flea vector induces a pretransmission innate immunity resistance phenotype in Yersinia pestis. PLoS Pathog 2010; 6:e1000783.
  • 20
    Sodeinde OA, Subrahmanyam YVBK, Stark K et al. A surface protease and the invasive character of plague. Science 1992; 258:10041007.
  • 21
    Lahteenmaki K, Kukkonen M, Korhonen TK. The Pla surface protease/adhesin of Yersinia pestis mediates bacterial invasion into human endothelial cells. FEBS Lett 2001; 504:6972.
  • 22
    Cowan C, Jones HA, Kaya YH et al. Invasion of epithelial cells by Yersinia pestis: evidence for a Yersinia pestis-specific invasin. Infect Immun 2000; 68:45234530.
  • 23
    Lathem WW, Price PA, Miller VL et al. A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science 2007; 315:509513.
  • 24
    Galvan EM, Lasaro MAS, Schifferli DM. Capsular antigen fraction 1 and pla modulate the susceptibility of Yersinia pestis to pulmonary antimicrobial peptides such as cathelicidin. Infect Immun 2008; 76:14561464.
  • 25
    Hinnebush BJ, Rudolph AE, Cherepanov P et al. Role of Yersinia murine toxin in survival of Yersinia pestis in the midgut of the flea vector. Science 2002; 296:733735.
  • 26
    Bennett LG, Tornabene TG. Characterization of the antigenic subunits of the envelope protein of Yersinia pestis. J Bacteriol 1974; 117:4855.
  • 27
    Tito MA, Miller J, Griffin KF et al. Macromolecular organisation of the Yersinia pestis capsular F1-antigen: insights from ToF mass spectrometry. Protein Sci 2001a; 10:24082413.
  • 28
    Du Y, Rosqvist R, Forsberg A. Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infect Immun 2002; 70:14531460.
  • 29
    Sebbane F, Jarrett C, Gardner D et al. The Yersinia pestis caf1M1A1 fimbrial capsule operon promotes transmission by flea bite in a mouse model of bubonic plague. Infect Immun 2009; 77:12221229.
  • 30
    Weening EH, Cathelyn JS, Kaufman G et al. The dependence of the Yersinia pestis capsule on pathogenesis is influenced by the mouse background. Infect Immun 2011; 79:644652.
  • 31
    Liu F, Chen H, Galvan EM et al. Effects of Psa and F1 on the adhesive and invasive interactions of Yersinia pestis with human respiratory tract epithelial cells. Infect Immun 2006; 74:56365644.
  • 32
    Davis KJ, Fritz DL, Pitt ML et al. Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction1-negative Yersinia pestis in African Green monkeys (Cercopithecus aethiops). Arch Pathol Lab Med 1996; 120:156163.
  • 33
    Zhou D, Han Y, Song Y et al. Genetics of metabolic variations between Yersinia pestis biovars and the proposal of a new biovar, microtus. J Bacteriol 2004; 186:51385146.
  • 34
    Skurnik M, Peippo A, Ervela E. Characterization of the O-antigen gene clusters of Yersinia pseudotuberculosis and the cryptic O-antigen gene cluster of Yersinia pestis shows that the plague bacillus is most closely related to and has evolved from Y. pseudotuberculosis serotype O:1b. Mol Microbiol 2000; 37:316330.
  • 35
    Suomalainen M, Haiko J, Ramu P et al. Using every trick in the book: the Pla surface protease of Yersinia pestis. Adv Exp Med Biol 2007; 603:268278.
  • 36
    Montminy SW, Khan N, McGrath S et al. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat Immunol 2006; 7:10661073.
  • 37
    Reithmeier-Rost D, Hill J, Williamson ED et al. The weak interaction of LcrV and TLR2 does not contribute to the virulence of Yersinia pestis. Microbes Dis 2007; 9:9971002.
  • 38
    Ben-Efraim S, Aronson M, Bichowsky-Slomnicki L. New antigenic component of Pasteurella pestis formed under specified conditions of pH and temperature. J Bacteriol 1961; 81:704714.
  • 39
    Lindler LE, Tall BD. Yersinia pestis pH-6 antigen forms fimbriae and is induced by intracellular association with macrophages. Mol Microbiol 1993; 8:311324.
  • 40
    Makoveichuk E, Cherepanov P, Lundberg S et al. pH6 antigen of Yersinia pestis interacts with plasma lipoproteins and cell membranes. J Lipid Res 2003; 44:320330.
  • 41
    Huang XZ, Lindler LE. The pH 6 antigen is an antiphagocytic factor produced by Yersinia pestis independent of yersinia outer proteins and capsule antigen. Infect Immun 2004; 72:72127219.
  • 42
    Zhou D, Han Y, Yang R. Molecular and physiological insights into plague transmission, virulence and etiology. Microbes Infect 2006; 8:273284.
  • 43
    Parkhill J, Wren BW, Thomson NR et al. Genome sequence of Yersinia pestis, the causative agent of plague. Nature 2001; 413:523527.
  • 44
    Ho DK, Riva R, Kirjavainen V et al. Functional recruitment of the human complement inhibitor C4BP to Yersinia pseudotuberculosis outer membrane protein Ail. J Immunol 2012; 188:44504459.
  • 45
    Hinnebusch BJ, Jarrett CO, Callison JA et al. Role of the Yersinia pestis Ail protein in preventing a protective polymorphonuclear leukocyte response during bubonic plague. Infect Immun 2011; 79:49844989.
  • 46
    Felek S, Krukonis ES. The Yersinia pestis Ail protein mediates binding and Yop delivery to host cells required for plague virulence. Infect Immun 2009; 77:825836.
  • 47
    Bartra SS, Styer KL, O'Bryant DM et al. Resistance of Yersinia pestis to complement-dependent killing is mediated by the Ail outer membrane protein. Infect Immun 2008; 76:612622.
  • 48
    Cornelis GR. The Yersinia Yop virulon, a bacterial system to subvert cells of the primary host defense. Folia Microbiol (Praha) 1998; 43:253261.
  • 49
    Burrows TW. An antigen determining virulence in Pasteurella pestis. Nature 1956; 177:426427.
  • 50
    Burrows TW, Bacon GA. The basis of virulence in Pasteurella pestis – the development of resistance to phagocytosis in vitro. Br J Exp Pathol 1956; 37:286299.
  • 51
    Pettersson J, Holmstrom A, Hill J et al. The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol Microbiol 1999; 32:961976.
  • 52
    Michiels T, Wattiau P, Brasseur R et al. Secretion of Yop proteins by yersiniae. Infect Immun 1990; 58:28402849.
  • 53
    Mueller CA, Broz P, Muller SA et al. The V-antigen of yersinia forms a distinct structure at the tip of injectisome needles. Science 2005; 310:674676.
  • 54
    Bos KI, Schuenemann VJ, Golding GB et al. A draft genome of Yersinia pestis from victims of the Black Death. Nature 2011; 478:444446.
  • 55
    Anderson GW, Leary SEC, Williamson ED et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun 1996; 64:45804585.
  • 56
    Reddin KM, Easterbrook TJ, Eley SM et al. A.comparison of the immunological and protective responses elicited by microencapsulated formulations of the F1 antigen from Yersinia pestis. Vaccine 1998; 16:761767.
  • 57
    Levy Y, Flashner Y, Tidhar A et al. T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague. Vaccine 2011; 29:68666873.
  • 58
    Hill J, Copse C, Leary S et al. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Y. pestis. Infect Immun 2003; 71:22342238.
  • 59
    Hill J, Leary SEC, Smither S et al. N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection. Vaccine 2009; 27:70737079.
  • 60
    Matson JS, Durick KA, Bradley DS et al. Immunization of mice with YscF provides protection from Yersinia pestis infections. BMC Microbiol 2005; 5:3855.
  • 61
    Leary SEC, Griffin KF, Galyov EE et al. Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague. Microb Pathog 1999; 26:159169.
  • 62
    Andrews GP, Strachan ST, Benner GE et al. Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and non-encapsulated Yersinia pestis. Infect Immun 1999; 67:15331537.
  • 63
    Benner GE, Andrews GP, Byrne WR et al. Immune response to Yersinia outer proteins and other Yersinia pestis antigens after experimental plague infection in mice. Infect Immun 1999; 67:19221928.
  • 64
    Swietncki W, Powell BS, Goodin J. Yersinia pestis Yop secretion protein F: purification, characterization, and protective efficacy against bubonic plague. Protein Expr Purif 2005; 42:166172.
  • 65
    Li B, Zhou L, Guo JY et al. High-throughput identification of new protective antigens from a Yersinia pestis live vaccine by enzyme-linked immunospot assay. Infect Immun 2009; 77:43564361.
  • 66
    Wang SX, Joshi S, Mboudjeka I et al. Relative immunogenicity and protection potential of candidate Yersinia pestis antigens against lethal mucosal plague challenge in Balb/c mice. Vaccine 2008; 26:16641674.
  • 67
    Williamson ED, Eley SM, Stagg AJ et al. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 1997; 15:10791084.
  • 68
    Cohen RJ, Stockard JL. Pneumonic plague in an untreated plague-vaccinated individual. J Am Med Assoc 1967; 202:365366.
  • 69
    Meyer KF. Effectiveness of live or killed plague vaccines in man. Bull World Health Organ 1970; 42:653666.
  • 70
    Williamson ED. Plague in: vaccines for biodefense, supplement to vaccine. Vaccine 2009; 27:D56D60.
  • 71
    Pitt MLM. Non-human primates as a model for pneumonic plague. Gaithersburg, MD: Animal Models and Correlates of Protection for Plague Vaccines Workshop, 2004.
  • 72
    Mett V, Lyons J, Musiychuk K et al. A plant-produced plague vaccine candidate confers protection to monkeys. Vaccine 2007; 25:30143017.
  • 73
    Stacy S, Pasquali A, Sexton VL et al. An age-old paradigm challenged: old baboons generate vigorous humoral immune responses to LcrV, a plague antigen. J Immunol 2008; 181:109115.
  • 74
    Cornelius CA, Quenee LE, Overheim KA et al. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect Immun 2008; 76:55885597.
  • 75
    Mizel SB, Graff AH, Sriranganathan N et al. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin Vaccine Immunol 2009; 16:2128.
  • 76
    Chichester JA, Musiychuk K, Farrance CE et al. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague. Vaccine 2009; 27:34713474.
  • 77
    Williamson ED, Packer PJ, Waters EL et al. Recombinant (F1+V) vaccine protects macaques against pneumonic plague. Vaccine 2011; 29:47714777.
  • 78
    Qiu Y, Liu Y, Qi Z et al. Comparison of immunological responses of plague vaccines F1+rV270 and EV76 in Chinese-origin rhesus macaque, Macaca mulatta. Scand J Immunol 2010; 72:425433.
  • 79
    Green M, Rogers D, Russell P et al. The SCID/Beige mouse as a model to investigate protection against Yersinia pestis. FEMS Immunol Med Microbiol 1999; 23:107113.
  • 80
    Jones SM, Griffin KF, Hodgson I et al. Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine 2003; 21:39123918.
  • 81
    Williamson ED, Flick- Smith HC, Waters EL et al. Immunogenicity of the rF1+rV vaccine with the identification of potential immune correlates of protection. Microb Pathogen 2007; 42:1222.
  • 82
    Fellows P, Adamovicz J, Hartings J et al. Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V). Vaccine 2010; 28:77487756.
  • 83
    Williamson ED, Flick-Smith HC, LeButt CS et al. Human immune response to a plague vaccine comprising recombinant F1 and rV antigens. Infect.Immun 2005; 73:35983608.
  • 84
    Lin J-S, Park S, Adamovicz JJ et al. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Vaccine 2011a; 29:357362.
  • 85
    Parent MA, Berggren KN, Kummer LW et al. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect Immun 2005; 73:73047310.
  • 86
    Williamson E, Dand Oyston PCF. Acellular vaccines against plague. In: Carniel E , Hinnebusch BJ , eds. Yersinia systems biology and control. Norfolk, UK: Caister Academic Press, 2012:123142.
  • 87
    Elvin SJ, Williamson ED. STAT 4 but not STAT 6 mediated immune mechanisms are essential in protection against plague. Microb Pathogen 2004; 37:177184.
  • 88
    Musson J, Morton M, Walker NJ et al. Sequential proteolytic processing of the capsular Caf1 antigen of Yersinia pestis for MHC class II-restricted presentation to T lymphocytes. J Biol Chem 2006; 281:2612926135.
  • 89
    Chalton DA, Musson JA, Flick-Smith HC et al. A functional monomeric plague vaccine created by circular permutation. Infect Immun 2006; 74:66246631.
  • 90
    Musson JA, Ingram R, Durand G et al. The repertoire of DR1-restricted CD4 T cell epitopes of the capsular Caf1 antigen of Y. pestis in human leucocyte antigen transgenic mice. Infect Immun 2010; 78:43564362.
  • 91
    Shim HK, Musson JA, Harper HM et al. Mechanisms of MHC class II-restricted processing and presentation of the V antigen of Yersinia pestis. Immunology 2006; 119:385392.
  • 92
    Hart MK, Saviolakis GA, Welkos SL, House RV. Advanced development of the rF1V and rBV A/B vaccines: progress and challenges. Adv Prev Med 2012; 2012: Article ID 731604, 14 pages; doi:10.1155/2012/731604.
  • 93
    US Food and Drug Administration Health and Human Services (FDA HHS). New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed Regist 2002; 67:3798837998.
  • 94
    Williamson ED, Duchars MG, Kohberg R. Recent advances in predictive models and correlates of protection in testing biodefence vaccines. Expert Rev Vaccines 2010; 9:527537.
  • 95
    Nemeth J, Straley SC. Effect of Yersinia pestis YopM on experimental plague. Infect Immun 1997; 65:924930.
  • 96
    Jones SM, Day F, Stagg AJ et al. Protection conferred by a fully-recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains. Vaccine 2001; 19:358366.
  • 97
    Arlen PA, Singleton M, Damovicz JJ et al. Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts. Infect Immun 2008; 76:36403650.
  • 98
    Quenee LE, Cilletti N, Berube B et al. Plague in guinea pigs and its prevention by subunit vaccines. Am J Pathol 2011; 178:16981700.
  • 99
    Anderson DM, Ciletti NA, Lee-Lewis H et al. Pneumonic plague pathogenesis and immunity in brown Norway rats. Am J Pathol 2009; 174:910921.
  • 100
    Rocke TE, Smith S, Marinari P et al. Vaccination with F1-V fusion protein protects black-footed ferrets (Mustela nigripes) against plague upon oral challenge with Yersinia pestis. J Wildl Dis 2008; 44:17.
  • 101
    Rocke TE, Smithh SR, Stinchcomb DT et al. Immunization of black-tailed prairie dog against plague through consumption of vaccine-laden baits. J Wildl Dis 2008; 44:930937.
  • 102
    Adamovicz JJ, Worsham PL. Plague. In: Swearengen JR , ed. Biodefense: research methodology and animal models. Boca Raton, USA: CRC Press, 2006:107135.